India markets closed
  • BSE SENSEX

    48,803.68
    +259.62 (+0.53%)
     
  • Nifty 50

    14,581.45
    +76.65 (+0.53%)
     
  • Dow

    33,730.89
    +53.62 (+0.16%)
     
  • Nasdaq

    13,857.84
    -138.26 (-0.99%)
     
  • BTC-INR

    4,699,471.50
    -137,016.50 (-2.83%)
     
  • CMC Crypto 200

    1,367.12
    -8.66 (-0.63%)
     
  • Hang Seng

    28,793.14
    -107.69 (-0.37%)
     
  • Nikkei

    29,642.69
    +21.70 (+0.07%)
     
  • EUR/INR

    89.8457
    -0.0970 (-0.11%)
     
  • GBP/INR

    103.5100
    +0.1142 (+0.11%)
     
  • AED/INR

    20.3590
    -0.0300 (-0.15%)
     
  • INR/JPY

    1.4461
    -0.0025 (-0.17%)
     
  • SGD/INR

    56.2510
    +0.0580 (+0.10%)
     

U.S. FDA authorizes J&J’s COVID-19 vaccine

U.S. regulators authorized Johnson & Johnson’s COVID-19 vaccine for emergency use Saturday – one day after a panel of outside experts backed the one-shot immunization.

Now that it has the blessing of the Food and Drug Administration, J&J plans to ship three to four million doses next week.

On Thursday, President Joe Biden, pledged to quickly distribute J&J’s vaccine pending its approval.

"We have a plan to roll it out as quickly as Johnson & Johnson can make it.”

More than 50 million vaccine shots have been administered nationwide – a point Biden highlighted as the halfway point of his goal of vaccinating 100 million people in the first 100 days after taking office.

Distribution of J&J’s vaccine is a lot easier than those already available in the U.S. made by Pfizer/BioNTech and Moderna.

Its vaccine can be stored in normal refrigerator temperatures instead of ultra-cold storage. And it’s the only one that requires just a single shot.

A trial found that J&J’s vaccine was 66% effective at preventing moderate-to-severe cases of COVID-19. And it was 100% effective at preventing hospitalizations 28 days after vaccination.

The company is developing a second-generation vaccine that would target the more transmissible South African variant. It plans to start Phase 1 trials by this summer.